...
首页> 外文期刊>Journal of the Formosan Medical Association =: Taiwan yi zhi >Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy
【24h】

Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy

机译:小分子血管破坏剂的肿瘤抗性机制:治疗和合适疗法的理由

获取原文
           

摘要

Small-molecule vascular disrupting agents (VDAs) target the established tumor blood vessels, resulting in rapidly and selectively widespread ischemia and necrosis of central tumor; meanwhile, blood flow in normal tissues is relatively unaffected. Although VDAs therapy is considered an important option for treatment, its use is still limited. The tumor cells at the periphery are less sensitive to vascular shutdown than those at the center, and subsequently avoid a nutrient-deprived environment. This phenomenon is referred to as tumor resistance to VDAs treatment. The viable periphery rim of tumor cells contributes to tumor regeneration, metastasis, and ongoing progression. However, there is no systematic review of the plausible mechanisms of repopulation of the viable tumor cells following VDAs therapy. The purpose of this review is to provide insights into mechanisms of tumor surviving small-molecule VDAs therapy, and the synergetic treatment to the remaining viable tumor cells at the periphery.
机译:小分子血管破坏剂(VDAs)靶向已建立的肿瘤血管,导致迅速且有选择性地普及中枢肿瘤的坏死;同时,正常组织中的血流相对不受影响。虽然VDAS治疗被认为是治疗的重要选择,但其使用仍然有限。周边的肿瘤细胞对比中心的血管关断敏感,并且随后避免营养不良的环境。这种现象称为肿瘤抗性对VDAS治疗。肿瘤细胞的可行周边边缘有助于肿瘤再生,转移和正在进行的进展。然而,在VDAS疗法后,没有对抑制活性肿瘤细胞的可合理机制的系统审查。本综述的目的是提供对肿瘤的机制存活小分子VDAS治疗的洞察力,以及对周边的剩余活肿瘤细胞的协同处理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号